{"analyses":[{"ciLowerLimit":"5.3","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"19.3","estimateComment":"The pre-specified threshold for the estimated percentage of MRD positivity at End Consolidation was set to 16%. Results show an upper bound on the (Agresti-Coull) confidence interval of 19.3%.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"=0.13","paramType":"percentage","paramValue":"10.5","statisticalMethod":"Binomial Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"19.3","value":"10.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"6.4","value":"0"},{"groupId":"OG002","lowerLimit":"39.6","upperLimit":"96.1","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used.","dispersionType":"90% Confidence Interval","groups":[{"description":"See Detailed Description\n\nAsparaginase: Given IT\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT or IV\n\nDasatinib: Given PO\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nHydrocortisone Sodium Succinate: Given IT\n\nIfosfamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeucovorin Calcium: Given IV or PO\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IT, PO, or IV\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPrednisone: Given PO or IV\n\nRadiation Therapy: Some patients undergo cranial RT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)"},{"description":"Based on Minimal Residual Disease, less than 1%.","id":"OG001","title":"Standard-risk"},{"description":"Based on Minimal Residual Disease, great than or equal to 1%.","id":"OG002","title":"High-risk"}],"paramType":"NUMBER","populationDescription":"Patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).","reportingStatus":"POSTED","timeFrame":"At end of consolidation (at 11 weeks)","title":"Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}